PDCD1 and lung carcinoma: compared the immune response of T cells in patients with active pulmonary TB and mice treated with MTB and lung cancer cells, and proved that MTB may inhibit Th1 immune response through the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) signaling pathway.